Evangelos S. Gragoudas, MD

Evangelos S. Gragoudas, MD

Charles Edward Whitten Distinguished Professor of Ophthalmology
Evangelos S. Gragoudas, MD

Research Area(s):AMDOcular Oncology

Mass Eye and Ear

Co-director, Laser Laboratory
Co-director, Retina Research Institute
Co-director, Ines and Frederick Yeatts Retina Research Laboratory
Senior Scientist


Harvard Catalyst Profile
Mass Eye and Ear Profile (Research)
Mass Eye and Ear Profile (Clinical)


Dr. Evangelos Gragoudas received his medical training in Athens, Greece, and completed ophthalmology residency training at Boston University School of Medicine. He completed a clinical fellowship in diabetic retinopathy at the Elliot P. Joslin Research Laboratory at Harvard Medical School, then a retina fellowship under Dr. Charles Schepens at Massachusetts Eye and Ear Infirmary. Dr. Gragoudas joined the full-time faculty at Mass Eye and Ear in 1975 and has served as Director of the Retina Service since 1985. He was promoted to Professor of Ophthalmology at Harvard Medical School in 1994.

Dr. Gragoudas is an international authority in retinal diseases and intraocular tumors. His translational research has benefited countless patients with ocular malignancies and retinal neovascular diseases. His early translational work focused on uveal melanoma, for which he pioneered the use of proton beam irradiation—a highly successful treatment that has been used in over 15,000 patients to date as a proven and safe alternative to enucleation (removal of the eye). Along with refining proton beam therapy, Dr. Gragoudas also has studied the epidemiology, genetics, and molecular biology of uveal melanoma to further improve diagnosis and treatment for this potentially fatal disease.

With a long-standing interest in retinal disorders, Dr. Gragoudas helped pioneer vascular-targeting therapies for neovascular diseases of the eye. In collaboration with Dr. Joan Miller, co-recipient of the 2014 Champalimaud Vision Award, Dr. Gragoudas developed photodynamic therapy using the light-sensitive dye verteporfin (Visudyne®). He was instrumental in designing and executing the early clinical studies, and was an integral member of the study and writing groups for the large clinical trials. Based on these large clinical trials, photodynamic therapy using Visudyne® became the first AMD treatment approved by the US Food and Drug Administration and international drug regulatory agencies.

Dr. Gragoudas also was among the first to target vascular endothelial growth factor (VEGF) in the treatment of AMD. This work was conducted in collaboration with the laboratory of famed anti-angiogenesis proponent, Dr. Judah Folkman, and with co-recipients of the 2014 Champalimaud Vision Award. This group first demonstrated the critical role of vascular endothelial growth factor (VEGF) in ocular neovascularization, and went on to demonstrate the inhibition of ocular neovascularization with VEGF inhibitors.

Dr. Gragoudas has published over 200 articles in peer-reviewed journals and authored more than 100 chapters, reviews, and books. He lectures nationally and internationally, and holds honorary doctorates from the University of Athens and the University of Patras, Greece. Some of his major honors and awards include the Academy Honor Award and the Senior Achievement Award from the American Academy of Ophthalmology, the Jules Gonin Lectureship of the Retina Research Foundation, the Senior Scientific Investigators Award from Research to Prevent Blindness, the J. Donald M. Gass Medal and the Arnall Patz Medal of the Macula Society, the Harvard Medical School Distinguished Alumni Award, and the Mildred Weisenfeld Award for Excellence in Ophthalmology from The Association for Research in Vision and Ophthalmology (ARVO).

Contact Information

243 Charles Street, Boston, MA 02114
T: 617-573-3515


Centers of Excellence and Institutes

All Faculty (Alphabetical by Last Name)